UCB buoyed by strong first half; lupus ambitions undented despite PhIII upset
This article was originally published in Scrip
The mid-sized European pharma company UCB is accelerating its investment in its early-stage portfolio following the continuing sales growth of its three core marketed products, and is also advancing a second potential lupus drug into Phase II trials following disappointing Phase III results reported earlier this week for its first lupus drug epratuzumab.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.